Can you stay on Wegovy long term? What the evidence says

What happens to weight when people stop, and why that shapes the long-term question?

One of the most striking findings from the semaglutide research programme is what happens after stopping. In the STEP 1 extension study, participants who had lost an average of around 15% of their body weight during 68 weeks of treatment regained roughly two-thirds of that within a year of discontinuing, as documented in the published trial data from the STEP 1 trial in the New England Journal of Medicine. That is not a criticism of the medicine, it reflects the biology of weight regulation. Semaglutide works by acting on GLP-1 receptors that govern appetite and gastric emptying; when the signal stops, appetite returns to its previous state.

Understanding this helps reframe the long-term question. Many people asking whether they can stay on Wegovy long term are really asking whether it is safe and supported to do so, and the evidence says yes, subject to clinical review. The question is not whether the medicine works; it is whether the prescriber judges continuation appropriate for your health profile over time.

It is entirely reasonable to feel uncertain about this. A medicine you may need to continue indefinitely sits differently in the mind than one with a clear end date, and that uncertainty deserves a straight answer rather than reassurance alone.

What does the NICE guidance say about how long treatment should last?

For NHS patients, NICE's appraisal of semaglutide (TA875) specifies a maximum of two years within a specialist weight management service. NICE also recommends that clinicians consider stopping if a patient has not achieved at least 5% weight loss after six months at the maintenance dose. Those parameters were set partly on cost-effectiveness grounds for the NHS and partly because longer-term trial data was more limited at the time of the appraisal.

Private treatment is not bound by that two-year ceiling in the same way, though it does not mean duration is open-ended without review. At nume, every repeat order is assessed by a GPhC-registered prescriber before it is approved, your current weight, how you are tolerating the medicine, and any changes to your health history are all considered. Continuing is never automatic. Explore the broader picture of Wegovy long-term use to understand how private prescribing approaches duration differently from the NHS pathway.

The practical upshot: duration is genuinely individual. Two years is a clinical anchor for NHS appraisal purposes, not a biological rule about when semaglutide stops being appropriate.

Are there known risks to consider with extended treatment?

The NHS medicines information for semaglutide covers the side-effect profile fully, and it is worth reading alongside any prescriber discussion. The most common effects (nausea, loose stools, constipation, reflux) are typically most prominent when the dose increases and tend to settle over days to weeks. For most people who have been on treatment for several months, these have already resolved or become manageable.

For longer-term use, the monitoring focus shifts: gallbladder disease is a recognised association with significant weight loss generally, not specific to semaglutide alone. Heart rate can increase modestly. Muscle mass requires attention, adequate protein and resistance activity matter more, not less, the longer someone is on treatment. A prescriber will factor all of this into periodic reviews. If you want to understand what the trial extensions tell us about safety signals over time, our page on the long-term effects of Wegovy covers the known evidence in more detail, and it sits alongside our guide to what those long-term effects of Wegovy actually mean in practice for people continuing treatment beyond the initial phase.

Pancreatitis is a known but infrequent serious risk with GLP-1 medicines; severe abdominal pain that reaches the back warrants urgent medical attention, at any stage of treatment. If anything changes in how you feel, contacting your prescriber rather than waiting for the next scheduled review is always the right call. Our support team is available seven days a week for exactly that reason.

How does an ongoing prescription actually work in practice?

For people who continue Wegovy beyond the initial titration phase, the process is less dramatic than the early weeks but no less important. The dose stays at whichever strength is both effective and tolerable; it is not automatically increased to the maximum. Prescribers look at sustained weight loss, side-effect burden, and any new health information before each repeat.

If you are considering starting or continuing Wegovy through an online pharmacy, the regulatory baseline is worth knowing: the pharmacy must be GPhC-registered and a qualified prescriber must review your case before each supply. That is a legal requirement, not a selling point. You can verify any pharmacy on the GPhC register before sharing any personal or health information with them.

At this stage, many patients find the question shifts from "will it work" to "how do I keep this working", which is where the lifestyle components (diet, activity, sleep, stress) become a bigger part of the conversation. The medicine creates the conditions; sustaining the result takes more than the pen alone, and our page on whether Wegovy works long term explores what the evidence says about maintaining results over time. Our prescribers are the right people to talk through a long-term plan with. Speak to our prescribers if you want an honest assessment of whether continuing treatment makes sense for you.